Immunotherapy for renal cell carcinoma

Katsunori Tatsugami, Momoe Itsumi

Research output: Contribution to journalReview articlepeer-review

57 Citations (Scopus)


Immunotherapy plays a significant role in the management of renal cell carcinoma (RCC) patients with metastatic disease because RCC is highly resistant to both chemotherapy and radiation therapy. Many reports illustrate various approaches to the treatment of RCC, such as cytokine-, antigen- or dendritic cell- (DC-) based immunotherapy, and the safety and effectiveness of immunotherapy have been highlighted by multiple clinical trials. Although antitumor immune responses and clinically significant outcomes have been achieved in these trials, the response rate is still low, and very few patients show long-term clinical improvement. Recently, the importance of immune regulation by antigen-presenting cells (APC) and regulatory T cells (Treg cells) has also been discussed. The authors outline the principles of cell-mediated tumor immunotherapy and discuss clinical trials of immunotherapy for RCC.

Original languageEnglish
Article number284581
JournalClinical and Developmental Immunology
Publication statusPublished - 2010

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Immunotherapy for renal cell carcinoma'. Together they form a unique fingerprint.

Cite this